全文获取类型
收费全文 | 760篇 |
免费 | 44篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 2篇 |
妇产科学 | 9篇 |
基础医学 | 105篇 |
口腔科学 | 1篇 |
临床医学 | 39篇 |
内科学 | 158篇 |
皮肤病学 | 4篇 |
神经病学 | 29篇 |
特种医学 | 58篇 |
外科学 | 184篇 |
综合类 | 2篇 |
预防医学 | 16篇 |
眼科学 | 4篇 |
药学 | 32篇 |
肿瘤学 | 136篇 |
出版年
2023年 | 7篇 |
2022年 | 5篇 |
2021年 | 22篇 |
2020年 | 8篇 |
2019年 | 11篇 |
2018年 | 29篇 |
2017年 | 17篇 |
2016年 | 30篇 |
2015年 | 29篇 |
2014年 | 53篇 |
2013年 | 55篇 |
2012年 | 67篇 |
2011年 | 82篇 |
2010年 | 53篇 |
2009年 | 36篇 |
2008年 | 47篇 |
2007年 | 53篇 |
2006年 | 36篇 |
2005年 | 33篇 |
2004年 | 30篇 |
2003年 | 26篇 |
2002年 | 17篇 |
2001年 | 18篇 |
2000年 | 16篇 |
1999年 | 7篇 |
1998年 | 1篇 |
1997年 | 5篇 |
1996年 | 1篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1986年 | 2篇 |
1984年 | 1篇 |
1982年 | 2篇 |
1961年 | 3篇 |
排序方式: 共有806条查询结果,搜索用时 15 毫秒
801.
Minkyu Jung MD Eun Hee Choi MS Chung Mo Nam PhD Sun Young Rha MD PhD Hei Cheul Jeung MD PhD Soo Hyun Lee MD Woo Ick Yang MD PhD Jae Kyung Roh MD PhD Hyun Cheol Chung MD PhD 《Annals of surgical oncology》2013,20(8):2615-2624
Background
Adjuvant! Online (AOL) is a Web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy for breast cancer.Methods
Using the Yonsei Tumor Registry database, patients with T1–3, N0–3, M0 breast cancer who were treated at the Yonsei Cancer Center between 1986 and 1999 were entered into AOL version 8.0 to calculate survival.Results
The median age of the study population was 45 years (range, 23–76 years) and the median follow-up duration was 10.8 years (range, 0.1–25.9 years) for all 699 patients. AOL significantly overestimated overall survival (OS) (by 11.1 %, P < 0.001), breast cancer-specific survival (BCSS) (by 11.6 %, P < 0.001), and event free-free survival (EFS) (by 9.25 %, P < 0.001) in Korean patients. Therefore, we developed a Korean version of AOL (KAOL), which is a new model for prognosis based on AOL’s parameters. The observed 10-year OS (61.4 %), BCSS (62.3 %), and EFS (59.1 %) and the KAOL predicted OS (61.5 %), BCSS (63.5 %) and EFS (57.6 %) were not different (P = 0.976, P = 0.771, and P = 0.674, respectively).Conclusions
AOL was not found to be suitable in Korean patients with breast cancer. The newly developed KAOL accurately predicted 10-year outcomes in Korean breast cancer patients. 相似文献802.
Rana R. McKay Nils Kroeger Wanling Xie Jae-Lyun Lee Jennifer J. Knox Georg A. Bjarnason Mary J. MacKenzie Lori Wood Sandy Srinivas Ulka N. Vaishampayan Sun-Young Rha Sumanta K. Pal Frede Donskov Srinivas K. Tantravahi Brian I. Rini Daniel Y.C. Heng Toni K. Choueiri 《European urology》2014
Background
The skeleton and liver are frequently involved sites of metastasis in patients with metastatic renal cell carcinoma (RCC).Objective
To analyze outcomes based on the presence of bone metastases (BMs) and/or liver metastases (LMs) in patients with RCC treated with targeted therapy.Design, setting, and participants
We conducted a review from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) of 2027 patients with metastatic RCC.Outcome measurements and statistical analysis
We analyzed the impact of the site of metastasis on overall survival (OS) and time-to-treatment failure. Statistical analyses were performed using multivariable Cox regression.Results and limitations
The presence of BMs was 34% overall, and when stratified by IMDC risk groups was 27%, 33%, and 43% in the favorable-, intermediate-, and poor-risk groups, respectively (p < 0.001). The presence of LMs was 19% overall and higher in the poor-risk patients (23%) compared with the favorable- or intermediate-risk groups (17%) (p = 0.003). When patients were classified into four groups based on the presence of BMs and/or LMs, the hazard ratio, adjusted for IMDC risk factors, was 1.4 (95% confidence interval [CI], 1.22–1.62) for BMs, 1.42 (95% CI, 1.17–1.73) for LMs, and 1.82 (95% CI, 1.47–2.26) for both BMs and LMs compared with other metastatic sites (p < 0.0001). The prediction model performance for OS was significantly improved when BMs and LMs were added to the IMDC prognostic model (likelihood ratio test p < 0.0001). Data in this analysis were collected retrospectively.Conclusions
The presence of BMs and LMs in patients treated with targeted agents has a negative impact on survival. Patients with BMs and/or LMs may benefit from earlier inclusion on clinical trials of novel agents or combination-based therapies. 相似文献803.
804.
805.
Ki-Chul Sung MD PhD Soon Jun Hong MD PhD Moo-Yong Rhee MD PhD Myung-Ho Jeong MD PhD Dae-Hee Kim MD PhD Sang-Wook Lim MD PhD Kyungil Park MD PhD Jin Bae Lee MD PhD Seok-Yeon Kim MD Jin-Man Cho MD PhD Goo-Yeong Cho MD PhD Jung-Ho Heo MD PhD Sang-Hyun Kim MD PhD Hae-Young Lee MD PhD Weon Kim MD PhD Deok-Kyu Cho MD Sungha Park MD PhD Jinho Shin MD PhD Wook-Bum Pyun MD PhD Kihwan Kwon MD PhD Seung-Woon Rha MD PhD Jin-A Jung PhD 《Journal of clinical hypertension (Greenwich, Conn.)》2023,25(5):429-439
We compared the efficacy and safety of third-standard-dose triple and third-standard-dose dual antihypertensive combination therapies in patients with mild to moderate hypertension. This was a phase II multicenter, randomized, double-blind, parallel-group trial. After a 4-week placebo run-in period, 245 participants were randomized to the third-dose triple combination (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg) or third-dose dual combination (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg, LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg, AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg) therapy groups and followed up for 8 weeks. The mean systolic blood pressure (BP) reduction was -18.3 ± 13.2, -13.0 ± 13.3, -16.3 ± 12.4, and -13.8 ± 13.2 mmHg in the ALC, AL, LC, and AC groups, respectively. The ALC group showed significant systolic BP reduction compared to the AL and AC groups at weeks 4 (P = .010 and P = .018, respectively) and 8 (P = .017 and P = .036, respectively). At week 4, the proportion of systolic BP responders was significantly higher in the ALC group (42.6%) than in the AL (22.0%), LC (23.3%), and AC (27.1%) groups (P = .013, P = .021, and P = .045, respectively). At week 8, the proportion of systolic and diastolic BP responders was significantly higher in the ALC group (59.7%) than in the AL (39.3%) and AC (42.4%) groups (P = .022 and P = .049, respectively) at week 8. Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension. 相似文献
806.
Yong Hoon Kim MD PhD Ae-Young Her MD PhD Seung-Woon Rha MD PhD FAHA FESC FSCAI FAPSIC Cheol Ung Choi MD PhD Byoung Geol Choi PhD Ji Bak Kim MD PhD Dong Oh Kang MD Ji Young Park MD PhD Sang-Ho Park MD PhD Myung Ho Jeong MD PhD 《Catheterization and cardiovascular interventions》2023,101(6):1014-1027
Clinical outcomes after non-ST-segment-elevation myocardial infarction (NSTEMI) in patients with (symptom-to-door time [SDT] ≥ 24 h) or without (SDT < 24 h) delayed hospitalization among patients with or without diabetes were compared. From the Korea Acute Myocardial Infarction Registry-National Institute of Health, a total of 4517 patients with NSTEMI who underwent new-generation drug-eluting stents implantation were recruited and they were classified into the diabetes mellitus (DM) and non-DM groups. These two groups were subdivided into groups with and without delayed hospitalization. The primary clinical outcome was the occurrence of major adverse cardiac and cerebrovascular events (MACCE), defined as all-cause death, recurrent myocardial infarction, repeat coronary revascularization, and stroke. The secondary clinical outcome was the occurrence of individual components of MACCE and stent thrombosis. Although after multivariable and propensity score-adjusted analyses in the DM group, the primary and secondary clinical outcomes between the SDT < 24 h and SDT ≥ 24 h groups were similar; in the non-DM group, all-cause (p = 0.003 and p = 0.007, respectively) and cardiac (p = 0.001 and p = 0.008, respectively) death rates were significantly higher in the SDT ≥ 24 h group than in the SDT < 24 h group. Our results suggested that there was no significant difference in prognosis between diabetic patients with and without delayed SDT, but delayed SDT was associated with poor prognosis in nondiabetic patients. 相似文献